Preclinical MOTS-c findings and a product-specific elamipretide approval.
Bottom line: Research on MOTS-c does not show that it slows aging in people. Forzinity's approval for Barth syndrome does not support that claim either. There is also no proven combined longevity protocol. [1–4]
| MOTS-c | SS-31 (Elamipretide) | |
|---|---|---|
| Identity | A mitochondrial-derived 16-amino-acid peptide. [1] | Elamipretide, a synthetic mitochondrial-targeting peptide; Forzinity is the approved product. [3] |
| Clinical use | The cited studies do not establish a routine human treatment. [1,2] | Forzinity improves muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Its accelerated approval requires confirmatory evidence of clinical benefit. [3] |
| Dose | No validated human longevity dose in these sources. [1,2] | Forzinity: 40 mg subcutaneously daily; 20 mg for adults with severe renal impairment who are not on dialysis. The label gives no recommendation for dialysis or pediatric renal impairment. [3] |
| Preparation | No validated patient preparation instructions in the cited studies. | Forzinity is a ready-to-use 80 mg/mL solution, 280 mg per 3.5 mL vial, not a powder to reconstitute. [3] |
tierA: {"tier":1,"label":"Preclinical treatment evidence"}
tierB: {"tier":3,"label":"Approved for a specific indication"}
summary: MOTS-c treatment improved outcomes in mice; the human exercise study measured naturally produced MOTS-c, not the effects of giving it to people. Elamipretide has been tested clinically, with results that depend on the disease and endpoint. [1–4]
trials: [{"name":"MOTS-c metabolic study","peptide":"a","n":"cells and mice","finding":"Mechanistic and mouse metabolic findings do not establish a human treatment dose.","pmid":"25738459"},{"name":"MOTS-c exercise study","peptide":"a","n":"human observations and mouse experiments","finding":"Human exercise induced endogenous MOTS-c; administered MOTS-c improved physical performance in mice.","pmid":"33473109"},{"name":"Elamipretide Barth syndrome trial","peptide":"b","n":"12 randomized","finding":"Neither primary endpoint was met in the randomized crossover phase. Improvements were reported in the uncontrolled extension; these are different evidence contexts.","pmid":"33077895"}]
No. It measured the body's MOTS-c response to exercise; the treatment experiments were in mice. [2]
No. Its participants had Barth syndrome, and the randomized phase did not meet its two primary endpoints. That study cannot establish a healthy-aging benefit. [4]
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
